Prescription drug abuse and misuse policy issues
Pain therapy access policy issues
Pain therapy access policy issues
None
Duration: February 20, 2017
to
October 1, 2019
General Issues: Health Issues , Medicare/Medicaid , Alcohol & Drug Abuse , Copyright/Patent/Trademark , Medical/Disease Research/Clinical Labs
Spending: about $1,121,316 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: Health & Human Services - Dept of (HHS), U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2019
Zyla Life Sciences (FKA Egalet Corporation) in-house lobbying effort was terminated on Jan. 16, 2020
Original Filing: 301106728.xml
3rd Quarter, 2019
In Q3, Zyla Life Sciences (FKA Egalet Corporation) did no lobbying for itself. The report was filed on Oct. 10, 2019.
Original Filing: 301064324.xml
2nd Quarter, 2019
In Q2, Zyla Life Sciences (FKA Egalet Corporation) did no lobbying for itself. The report was filed on July 15, 2019.
Original Filing: 301045452.xml
1st Quarter, 2019
In 1A, Egalet Corporation did no lobbying for itself. The report was filed on May 23, 2019.
Original Filing: 301041366.xml
1st Quarter, 2019
In Q1, Egalet Corporation did no lobbying for itself. The report was filed on April 17, 2019.
Original Filing: 301027113.xml
4th Quarter, 2018
In Q4, Egalet Corporation had in-house lobbyists. The report was filed on Jan. 18, 2019.
Original Filing: 301008635.xml
Lobbying Issues
Prescription drug abuse and misuse policy issues
Pain therapy access policy issues
Agencies Lobbied
Health & Human Services - Dept of (HHS) U.S. Senate U.S. House of Representatives
Lobbying Issues
Pain therapy access policy issues
Agencies Lobbied
Health & Human Services - Dept of (HHS)
3rd Quarter, 2018
In Q3, Egalet Corporation had in-house lobbyists. The report was filed on Oct. 19, 2018.
Original Filing: 300991307.xml
Lobbying Issues
Prescription drug abuse and misuse policy issues
H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids
H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology
H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids
Abuse-deterrent opioid policy issues
Pain therapy access policy issues
S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription drug abuse policy issues
Provisions related to abuse-deterrent opioid formulary placement
Provisions related to abuse-deterrent opioid coverage and access in Medicare
H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare
S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2018
In Q2, Egalet Corporation had in-house lobbyists. The report was filed on July 19, 2018.
Original Filing: 300970995.xml
Lobbying Issues
Prescription drug abuse and misuse policy issues
H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids
H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology
H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids
Abuse-deterrent opioid policy issues
Pain therapy access policy issues
S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription drug abuse policy issues
Provisions related to abuse-deterrent opioid formulary placement
Provisions related to abuse-deterrent opioid coverage and access in Medicare
H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare
S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2018
In Q1, Egalet Corporation had in-house lobbyists. The report was filed on April 20, 2018.
Original Filing: 300955175.xml
Lobbying Issues
Prescription drug abuse and misuse policy issues
H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids
H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology
H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids
Abuse-deterrent opioid policy issues
Pain therapy access policy issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription drug abuse policy issues
Provisions related to abuse-deterrent opioid formulary placement
Provisions related to abuse-deterrent opioid coverage and access in Medicare
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2017
In Q4, Egalet Corporation had in-house lobbyists. The report was filed on Jan. 11, 2018.
Original Filing: 300922669.xml
Lobbying Issues
Prescription drug abuse and misuse policy issues
H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids
Abuse-deterrent opioid policy issues
Pain therapy access policy issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription drug abuse policy issues
Provisions related to abuse-deterrent opioid formulary placement
Provisions related to abuse-deterrent opioid coverage and access in Medicare
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2017
In Q3, Egalet Corporation had in-house lobbyists. The report was filed on Oct. 23, 2017.
Original Filing: 300917322.xml
Lobbying Issues
Prescription drug abuse and misuse policy issues
H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids
Abuse-deterrent opioid policy issues
Pain therapy access policy issues
S. 1049, provisions related to physician education on abuse-deterrent opioid products
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
Prescription drug abuse policy issues
Provisions related to abuse-deterrent opioid formulary placement
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
Lobbying Issues
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Agencies Lobbied
U.S. House of Representatives U.S. Senate White House Office
2nd Quarter, 2017
In Q2, Egalet Corporation had in-house lobbyists. The report was filed on July 27, 2017.
Original Filing: 300898629.xml
Lobbying Issues
Prescription drug abuse and misuse policy issues
H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids
H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids
H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act
1st Amendment/Communications with payors/off-label policy issues
Abuse-deterrent opioid policy issues
Pain therapy access policy issues
S. 1049, provisions related to physician education on abuse-deterrent opioid products
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription drug abuse policy issues
Provisions related to abuse-deterrent opioid formulary placement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Abuse-deterrent opioid exclusivity policy issues
H.R. 2025, provisions related to abuse-deterrent opioid exclusivity
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to DEA quotas of Schedule I and II controlled substances
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2017
In Q1, Egalet Corporation had in-house lobbyists. The report was filed on April 19, 2017.
Original Filing: 300871023.xml
Lobbying Issues
Prescription drug abuse and misuse policy issues
H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids
H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids
Provisions related to the reauthorization of the Prescription Drug User Fee Act
1st Amendment/Communications with payors/off-label policy issues
Abuse-deterrent opioid policy issues
Pain therapy access policy issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Prescription drug abuse policy issues
Provisions related to abuse-deterrent opioid formulary placement
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Provisions related to abuse-deterrent opioid exclusivity
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to DEA quotas of Schedule I and II controlled substances
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate